LOGIN
Synthetic cannabinoid improves neuropathic pain compared to placebo without psychoactive effects
October 2018
Synthetic cannabinoid improves neuropathic pain compared to placebo without psychoactive effects
Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial
JAMA. 2003 Oct 1;290(13):1757-62.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
21 patients with chronic neuropathic pain received increasing doses of a synthetic cannabinoid (CT-3) or placebo for 1 week in a random order. The primary outcome was pain reduction, measured by the Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS). Psychoactive effects were also assessed by the Trail-Making Test (TMT) and Addiction Research Center Inventory-Marijuana (ARCI-M), and adverse...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.